Foresee Pharmaceuticals Announces Submission of the NDA to the U.S. FDA for the 3-month Version of CAMCEVI for the Treatment of Advanced Prostate Cancer

Posted on by

TAIPEI, Oct. 29, 2024 /PRNewswire/ — Foresee Pharmaceuticals Co., Ltd. (TPEx: 6576), (“Foresee”) announced today that it has submitted a 505(b)(2) New Drug Application for the 3-month version of CAMCEVI, a ready-to-use 3-month depot formulation of leuprolide mesylate, to the U.S. Food…